CoChat

Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation

Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., Jenssen, T. · 2014 · Nephrology Dialysis Transplantation

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

BACKGROUND: New-onset diabetes after transplantation (NODAT) is a common complication after renal transplantation. There are limited available oral drugs to treat hyperglycaemia in this population owing to reduced renal function, potential interactions with immunosuppressive drugs and adverse effects such as hypoglycaemic events that may increase the cardiovascular risk. This study was initiated to investigate efficacy and safety of sitagliptin treatment that may represent a novel alternative in renal transplant recipients. METHODS: Nineteen long-term stable renal transplant recipients with NODAT were included in a controlled, cross-over study and randomized to first receive either sitagliptin 50-100 mg/day or a sitagliptin-free period of 4 weeks. Median age (interquartile range, IQR) was 67 (62-72) years (12 males/7 females), all studied 1 (1-3) year after transplantation. The immunosuppressive regimen was a triple calcineurin inhibitor-based therapy. Oral glucose tolerance test (OGTT) with insulin and C-peptide responses and laser Doppler (LD) flowmetry assessment of endothelial function were performed at baseline and after each treatment period. Home measurements of plasma glucose were performed daily during the study. RESULTS: The median (IQR) first- and second-phase insulin secretion responses increased significantly by 56.3% (45.2-112.6%, P = 0.005) and 39.3% (26.5-81.0%, P = 0.006), respectively, following sitagliptin treatment as compared with no sitagliptin treatment. Fasting and 2-h plasma glucose concentrations fell significantly {0.9 mmol/L [0.5-1.7 mmol/L (16.2 mg/dL), P = 0.003] and 2.9 mmol/L [0.5-6.4 mmol/L (52.3 mg/dL), P = 0.004], respectively}, as did also home measurements of plasma glucose. Endothelial function and plasma markers of cardiovascular risk were unaffected. No serious adverse events were observed. Two mild and asymptomatic hypoglycaemic episodes were observed in combination with glipizide. CONCLUSIONS: Sitagliptin increases insulin secretion and reduces fasting and postprandial plasma glucose in renal transplant recipients with NODAT. The short-term treatment was well tolerated, and sitagliptin seems safe in this population.

Overview

Integrity signals

Registry

Crossref · 10.1093/ndt/gft536

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 3

  1. 2012, 2012, 569
  2. Li, 2011, Chinese medical journal, 124, 3607
  3. Kubota, 2012, 4, 309

Cited by

See all 94

Metadata

Authors
Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T.
Affiliations
Oslo University Hospital (NO)
Venue
Nephrology Dialysis Transplantation
Published
2014-01-22
Volume
29
Issue
4
Pages
926-933
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2171947907
Cited by
89
References
55
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 14 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 3 · 2016: 10 · 2015: 12 · 2014: 5
FWCI
8.04
Type
journal article
Language
en
Open access
closed
Locations
  • Nephrology Dialysis Transplantation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
post-transplant diabetes mellitus, kidney transplantation, DPP-4 inhibitors, insulin secretion, hyperglycemia, endothelial function, cardiovascular risk markers, hypoglycemia, glipizide, immunosuppressive therapy, plasma glucose control, oral glucose tolerance test, insulin resistance, drug safety and tolerability, crossover trial
MeSH terms
Sitagliptin Phosphate, Aged, Blood Glucose, Diabetes Mellitus, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Prospective Studies, Pyrazines, Risk Factors, Time Factors, Triazoles, Kidney Transplantation, Treatment Outcome, Cross-Over Studies, Postprandial Period, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. https://app.cochat.ai/papers/10.1093/ndt/gft536
The paper
Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T. (2014). Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gft536

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.